Resource library

This package outlines the next steps and what the options are to make a significant difference in opioid-induced adverse drug events.

New dosing guidance for acetylcysteine for the treatment of paracetamol overdose and toxicity issued in January 2019.

Following international practice, the name and strength description for Bicillin LA® has been changed. The expression of the name will now be benzathine benzylpenicillin tetrahydrate. The expression of product strength will now be 1,200,000 units/2.3

Tools developed by Waitematā DHB to encourage the safer prescribing and the best practice use of oxygen therapy, to reduce harm to patients.

Techniques for reviewing an event and implementing change and improvements.

Guidelines for the display of combination product medicines in electronic systems.

Purpose: To highlight the risks associated with the use of transdermal patches (both from the medicine and the delivery system).

The Health Quality & Safety Commission, Choosing Wisely and the Australian and New Zealand College of Anaesthetists have developed an information leaflet to help patients, caregivers and whānau use opioid medicines safely, to manage non-cancer pain.

A booklet and a flyer from ACC with information for people who could get pregnant, and their families and whānau, understand the risks and benefits of taking anti-seizure medicines for epilepsy, mental health and pain.

The 2020 Annual Report of the Australian & New Zealand Hip Fracture Registry 2020 Annual Report.